Whereas TROP-2 IHC expression in papillary carcinoma was 89.2% (33/37), which approximates the results of other studies by Abdou et al. (71.4%), Bychkov et al. (81.5%), and Liu et al. (81.6%).21,25,26. This evidence concerns the gene TACSTD2 and papillary carcinoma.